Effect of atorvastatin on intraabdominal fat and microalbuminuria in patients with metabolic syndrome

徐兴森; 闫振成; 刘浩宇; 钟健; 邹密; 倪银星; 陈静; 祝之明

您当前的位置：

首页 >

文章列表页 >

Effect of atorvastatin on intraabdominal fat and microalbuminuria in patients with metabolic syndrome

更新时间：2026-01-09

- Effect of atorvastatin on intraabdominal fat and microalbuminuria in patients with metabolic syndrome
- Journal of Army Medical University Vol. 30, Issue 15, Pages: 1478-1480(2008)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R589.05;R692;R972.6
- Published：2008
- 稿件说明：
移动端阅览
徐兴森,闫振成,刘浩宇,钟健,邹密,倪银星,陈静,祝之明.阿托伐他汀对代谢综合征腹内脂肪及其肾损害的影响[J].陆军军医大学学报(原第三军医大学学报),2008,30(15):1478-1480.

　XU Xing-sen,YAN Zhen-cheng,LIU Hao-yu,ZHONG Jian,ZOU Mi,NI Yin-xing,CHEN Jing,ZHU Zhi-ming.Effect of atorvastatin on intraabdominal fat and microalbuminuria in patients with metabolic syndrome[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(15):1478-1480.
徐兴森,闫振成,刘浩宇,钟健,邹密,倪银星,陈静,祝之明.阿托伐他汀对代谢综合征腹内脂肪及其肾损害的影响[J].陆军军医大学学报(原第三军医大学学报),2008,30(15):1478-1480. DOI：

　XU Xing-sen,YAN Zhen-cheng,LIU Hao-yu,ZHONG Jian,ZOU Mi,NI Yin-xing,CHEN Jing,ZHU Zhi-ming.Effect of atorvastatin on intraabdominal fat and microalbuminuria in patients with metabolic syndrome[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(15):1478-1480. DOI：

摘要

目的观察阿托伐他汀对代谢综合征（metabolic syndrome

MS）的腹内脂肪的影响及其与肾损害的关系。方法 2004-2006年曾在我科住院并诊断为MS的患者44例，按随机数字表法分成2组，在严格控制血压血糖的基础上，治疗组加用阿托伐他汀10 mg

1次/d；对照组不予任何调脂药，观察两组血压、血糖、体质量、腹壁、腹内脂肪厚度及尿微量白蛋白（MAU）在12周治疗前后的变化。结果治疗组12周后患者的腹内脂肪厚度显著减少[非ACEI/ARB治疗：(41.76±3.61)mm vs (33.23±2.47)mm；ACEI/ARB治疗：（42.86±3.49）mm vs (30.49±2.87)mm，P0.01]，尿微量白蛋白明显下降[非ACEI/ARB治疗：(77.59±20.90)mg/24 h vs （35.20±14.45）mg/24 h；ACEI/ARB治疗：（78.39±19.78）mg/24 h vs (32.91±13.87) mg/24 h

P0.05]。多因素分析显示对MAU增多有影响的危险因素依次为空腹血糖、甘油三酯、收缩压、年龄、腹内脂肪。结论阿托伐他汀可减少MS的腹内脂肪厚度，并对肾损害有保护作用

可能与减少内脏脂肪有关。

Abstract

Objective To observe the effect of atorvastatin on intraabdominal fat and microalbuminuria (MAU) in patients with metabolic syndrome (MS). Methods Forty-four MS patients were divided into the atorvastatin group and the control group. Blood pressure and blood glucose were controlled in both groups

in addition

atorvastatin was administered to the patients in the atorvastatin group. Blood pressure

blood glucose

body weight

abdominal wall fat

intraabdominal fat and MAU were compared before and after 12 weeks’ treatment. Results Obvious decrease of the intraabdominal fat and MAU was found in the atorvastatin group compared with those before the treatment [Intraabdominal fat: non-ACE1/ARB (41.76±3.61) mm vs (33.23±2.47) mm

P0.01; ACEI/ARB：（42.86±3.49）mm vs (30.49±2.87)mm

P0.01; MAU: (77.59±20.90) mg/24 h vs (35.20±14.45) mg/24 h; ACEI/ARB：（78.39±19.78）mg/24 h vs (32.91±13.87) mg/24 h

P0.05]. Binary logistic regression analysis showed fasting glucose

SBP

age and intraabdominal fat were independent risk factors of MAU. Conclusion Atorvastatin could decrease the intraabdominal fat and protect against renal lesion.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Potential mechanism of metabolic syndrome related cognitive impairment: Mediation effect of thyroid-stimulating hormone in schizophrenia patients

Correlation of metabolic syndrome and its components with arterial stiffness among rural residents in Beijing

Effect of high-dose statins in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis and systematic review

Effects of hemoperfusion on lipid profiles and blood pressure in patients with metabolic syndrome

Survey on exercise status and risk factors for metabolic syndrome in convalescents from a military sanatorium

Related Author

ZHANG Qinghui

WANG Yuhan

WANG Nanlian

XIA Keyan

HU Hua

AI Liying

王紫荆

胡永华

Related Institution

Department of Psychiatry， Key Laboratory of Major Brain Diseases and Aging of Ministry of Education， Psychiatric Medical Center， the First Affiliated Hospital of Chongqing Medical University

Chongqing Mental Health Center

⁰